ATE334217T1 - Alphavirus-vektoren - Google Patents

Alphavirus-vektoren

Info

Publication number
ATE334217T1
ATE334217T1 AT98954098T AT98954098T ATE334217T1 AT E334217 T1 ATE334217 T1 AT E334217T1 AT 98954098 T AT98954098 T AT 98954098T AT 98954098 T AT98954098 T AT 98954098T AT E334217 T1 ATE334217 T1 AT E334217T1
Authority
AT
Austria
Prior art keywords
alphavirus
alphavirus vectors
vector
host
following administration
Prior art date
Application number
AT98954098T
Other languages
English (en)
Inventor
Mark Parrington
Michel Klein
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE334217T1 publication Critical patent/ATE334217T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
AT98954098T 1997-11-14 1998-11-13 Alphavirus-vektoren ATE334217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6579397P 1997-11-14 1997-11-14

Publications (1)

Publication Number Publication Date
ATE334217T1 true ATE334217T1 (de) 2006-08-15

Family

ID=22065156

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98954098T ATE334217T1 (de) 1997-11-14 1998-11-13 Alphavirus-vektoren

Country Status (11)

Country Link
EP (1) EP1029069B9 (de)
JP (1) JP3835669B2 (de)
AT (1) ATE334217T1 (de)
AU (1) AU753729B2 (de)
BR (1) BR9814171A (de)
CA (1) CA2309835A1 (de)
DE (1) DE69835369T2 (de)
DK (1) DK1029069T3 (de)
ES (1) ES2268797T3 (de)
PT (1) PT1029069E (de)
WO (1) WO1999025859A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
CN1927403B (zh) * 2006-09-29 2010-09-29 张永亮 用于促进仔猪生长、提高仔猪免疫力的药物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines

Also Published As

Publication number Publication date
WO1999025859A1 (en) 1999-05-27
CA2309835A1 (en) 1999-05-27
PT1029069E (pt) 2006-12-29
DE69835369T2 (de) 2007-08-23
ES2268797T3 (es) 2007-03-16
DK1029069T3 (da) 2006-12-18
JP3835669B2 (ja) 2006-10-18
DE69835369D1 (de) 2006-09-07
AU753729B2 (en) 2002-10-24
AU1139199A (en) 1999-06-07
EP1029069B9 (de) 2006-12-27
EP1029069B1 (de) 2006-07-26
BR9814171A (pt) 2001-10-30
JP2002508925A (ja) 2002-03-26
EP1029069A1 (de) 2000-08-23

Similar Documents

Publication Publication Date Title
ATE278790T1 (de) Mischung von rekombinanten vakzine-vektoren als polyeur-impfstoff gegen hiv
ITMI992125A0 (it) Alcossiammine eterocicliche come regolatori ub procedimenti di polimer izzazione a radicali controllati
NO950550L (no) Sulfonylalkanoylamino-hydroksyetylaminosulfonamider som er nyttige som retrovirale proteaseinhibitorer
DK1037634T3 (da) Oral administrationsform som omfatter en protonpumpeinhibitor (fx pantoprazo)
FR2765794B1 (fr) Dispositif d'eveinage notamment pour endoeveinage
ATE338546T1 (de) Effektoren von dipeptidylpeptidase iv
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
ATE334217T1 (de) Alphavirus-vektoren
DE69005416D1 (de) Stabilisierung von konzentrierten Wasserstoffperoxydlösungen.
NO964628L (no) DNA-sekvenser
FI940867A (fi) Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia
ES2138401T3 (es) Fuente de alimentacion de modo conmutado con modo de espera con poca perdida de potencia.
ATE323166T1 (de) Fragmente der intron a von citomegalovirus
MY132298A (en) Ironing aid
TR199801002A3 (tr) Selülozik lifli materyallerin çapraz-baglantisi.
DE69807213T2 (de) Augenschutz gegen chirurgische laserenergie
AU4765396A (en) Method of preparing retroviral protease inhibitor intermediates
BR9806321A (pt) Processo e composição para inibir a polimerização durante a produção anaeróbica de estireno.
ATE235219T1 (de) Kosmetische zubereitungen
DE69014298T2 (de) Stabilisierung von wasserstoffperoxydlösungen.
ES2174113T3 (es) Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
ES2144748T3 (es) Dispositivo y procedimiento para la produccion de material estirado.
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
CA2339345A1 (en) Optical communications system and method of protecting an optical route
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1029069

Country of ref document: EP

REN Ceased due to non-payment of the annual fee